Guggenheim Reiterates Buy on Enliven Therapeutics, Maintains $78 Price Target

Benzinga · 3d ago
Guggenheim analyst Michael Schmidt reiterates Enliven Therapeutics (NASDAQ:ELVN) with a Buy and maintains $78 price target.